2015
DOI: 10.15586/jkcvhl.2015.24
|View full text |Cite
|
Sign up to set email alerts
|

Present and future perspectives on immunotherapy for advanced renal cell carcinoma: Going to the core or beating around the bush?

Abstract: Metastatic lesions of renal cell carcinoma (RCC) occasionally regress spontaneously after surgical removal of the primary tumor. Although this is an exceptionally rare occurrence, RCC has thus been postulated to be immunogenic. Immunotherapies, including cytokine therapy, peptide-based vaccines, and immune checkpoint inhibitors have therefore been used to treat patients with advanced, metastatic RCC. We review the history, trends, and recent progress in immunotherapy for advanced RCC and discuss future perspec… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 29 publications
(35 reference statements)
0
1
0
Order By: Relevance
“…Immunotherapy plays an important role in the treatment of renal cell carcinoma (RCC) (1, 2). Cytokines have been used for a long time as the mainstay of immunotherapy for clear cell RCC (ccRCC).…”
Section: Introductionmentioning
confidence: 99%
“…Immunotherapy plays an important role in the treatment of renal cell carcinoma (RCC) (1, 2). Cytokines have been used for a long time as the mainstay of immunotherapy for clear cell RCC (ccRCC).…”
Section: Introductionmentioning
confidence: 99%